Genetic Expression and Prediction of Response to Neoadjuvant Docetaxel or Doxorubicin in Locally Advanced Breast Cancer
Status:
Completed
Trial end date:
2009-05-01
Target enrollment:
Participant gender:
Summary
After a core biopsy of the tumor is obtained, patients with locally advanced breast cancer
are randomized to receive 4 cycles of full dose doxorubicin (75 mg/m2 e3w) or docetaxel (100
mg/m2 e3w). After the fourth cycle, patients are submitted to surgery to ascertain
pathological response. They then receive the opposite drug, hormones, Herceptin, and
radiation as indicated.